These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25867204)

  • 21. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
    Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
    Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing.
    Lally K; Kruse RL; Smetana H; Davis R; Roots A; Marshall C; Ness PM; DeZern AE; Gladstone DE; Brennan DC; Desai NM; Tobian AAR; Bloch EM; Gehrie EA
    Transfusion; 2020 Mar; 60(3):628-636. PubMed ID: 31957889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.
    Menis M; Sridhar G; Selvam N; Ovanesov MV; Divan HA; Liang Y; Scott D; Golding B; Forshee R; Ball R; Anderson SA; Izurieta HS
    Am J Hematol; 2013 Dec; 88(12):1035-40. PubMed ID: 23907744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy.
    Mohamed M; Bates G; Eastley B
    Br J Haematol; 2013 Mar; 160(5):570. PubMed ID: 23294261
    [No Abstract]   [Full Text] [Related]  

  • 29. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.
    Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM
    Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin.
    Sinclair CJ; Brooks W; Genereux MG
    Biologicals; 2008 Jul; 36(4):256-62. PubMed ID: 18406165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemolytic adverse events with immune globulin products: product factors and patient risks.
    Scott DE; Epstein JS
    Transfusion; 2015 Jul; 55 Suppl 2():S2-5. PubMed ID: 26174893
    [No Abstract]   [Full Text] [Related]  

  • 32. [Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin].
    Juel J; Markvardsen LH; Jakobsen J
    Ugeskr Laeger; 2011 Aug; 173(33):1963-4. PubMed ID: 21849136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABO-immunoglobulin G antibodies in intravenous immune globulin can interfere in ABO-mismatched kidney transplants.
    Boctor FN; Bhaskaran M; Sheahan B; Heaton WA; Molmenti E
    Transfusion; 2011 Aug; 51(8):1874-5. PubMed ID: 21831188
    [No Abstract]   [Full Text] [Related]  

  • 34. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: An open-label prospective trial.
    Akman AO; Kara FK; Koksal T; Cakir BC; Karagol C; Sayli T
    Transfus Apher Sci; 2017 Aug; 56(4):531-534. PubMed ID: 28818402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic events associated with immunoglobulin treatment.
    Funk MB; Gross N; Gross S; Hunfeld A; Lohmann A; Guenay S; Hanschmann KM; Keller-Stanislawski B
    Vox Sang; 2013 Jul; 105(1):54-64. PubMed ID: 23398249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.